Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Int. braz. j. urol ; 44(5): 972-980, Sept.-Oct. 2018. tab, graf
Artigo em Inglês | LILACS | ID: biblio-975624

RESUMO

ABSTRACT Purpose: To evaluate the impact of overactive bladder disorder on patients diagnosed with retrograde ejaculation. Materials and Methods: Retrospective analysis of prospective collected database made. Questionnaires conducted in urology polyclinics in five different centers. Main Outcome Measure(s): International Index of Erectile Function - 5 (IIEF - 5), Overactive Bladder 8 - Question Awareness Tool (OAB - V8), urodynamics, semen analysis. The participants of the study were n = 120 patients. There was retrograde ejaculation (RE) in only n = 47 patients (non / minimal symptomatic patients), n = 73 patients had RE and overactive (OAB) complaints (symptomatic patients) and received anticholinergic treatment (trospium), n = 37 control group patients who only had OAB and received an anticholinergic. Results: While no difference was observed in overactive bladder examination and urodynamic values between the non / minimal symptomatic group and the symptomatic group (p > 0.05), sperm was detected and identified as fructose positive in post - ejaculation urine in the symptomatic group. Thus, it was possible to demonstrate the differences between symptomatic patients and non - symptomatic patients. Consequently, following three - month daily treatment with trospium 30 mg 2 x 1 in the control group and the symptomatic group, it was observed that an evident increase was observed in the sperm count and ejaculate volume in the symptomatic group and that no change was observed in the control group (p < 0.05). Conclusion: This clinical study is the first of its kind in terms of revealing the coexistence of RE with OAB upon performing urodynamics and showing that treatment is possible in selected patients.


Assuntos
Humanos , Masculino , Adulto , Oligospermia/complicações , Antagonistas Colinérgicos/uso terapêutico , Ejaculação/fisiologia , Bexiga Urinária Hiperativa/complicações , Oligospermia/fisiopatologia , Oligospermia/tratamento farmacológico , Contagem de Espermatozoides , Estudos de Casos e Controles , Estudos Retrospectivos , Bexiga Urinária Hiperativa/fisiopatologia , Bexiga Urinária Hiperativa/tratamento farmacológico
2.
Int. braz. j. urol ; 44(4): 794-799, July-Aug. 2018. tab
Artigo em Inglês | LILACS | ID: biblio-954085

RESUMO

ABSTRACT Objective: Melatonin is a hormone secreted from the pineal gland and has anti-oxidative and anti-inflammatory effects. Oxidative stress is considered as an important factor in the etiology of erectile dysfunction (ED), and in many experimental models, positive results have been obtained with melatonin treatment. This study aimed to measure serum melatonin levels in ED patients and to investigate the possible relationship between ED and melatonin levels. Materials and Methods: Sixty-two patients diagnosed with mild, moderate or severe ED according to the five-item International Erectile Function Index (IIEF-5) and 22 healthy individuals were included in the study. The serum melatonin levels, anthropometric data, and other biochemical and hormonal parameters of all the subjects were recorded. Detailed anamnesis was also obtained in terms of diabetes, hypertension, cardiovascular diseases, smoking status, and alcohol use. Results: The serum melatonin level was found 34.2±13.3 ng/dL in the mild ED group, 33.3±14.7 ng/dL in the moderate ED group, 34.8±17.2 ng/dL in the severe ED group, and 44.6±16.5 ng/dL in the control group. The serum melatonin levels were significantly lower in all ED groups compared to the control group (p=0.019). There was no significant difference in the serum melatonin levels between the three ED groups. Diabetes, hypertension, cardiovascular diseases, smoking and alcohol use were not significantly different between the ED groups (p>0.05). Conclusion: We consider that if our findings are supported by further studies with larger populations, the measurement of the serum melatonin level may have a future role in the diagnosis and treatment of ED.


Assuntos
Humanos , Masculino , Disfunção Erétil/etiologia , Disfunção Erétil/sangue , Melatonina/deficiência , Melatonina/sangue , Triglicerídeos/sangue , Índice de Gravidade de Doença , Ensaio de Imunoadsorção Enzimática , Biomarcadores/sangue , Doenças Cardiovasculares/complicações , Fumar/efeitos adversos , Estudos de Casos e Controles , Colesterol/sangue , Fatores de Risco , Estatísticas não Paramétricas , Estresse Oxidativo , Complicações do Diabetes , Hipertensão/complicações , Pessoa de Meia-Idade
3.
Int. braz. j. urol ; 43(2): 317-324, Mar.-Apr. 2017. tab
Artigo em Inglês | LILACS | ID: biblio-840825

RESUMO

ABSTRACT Objective To investigate the effect of a 5mg daily tadalafil treatment on the ejaculation time, erectile function and lower urinary tract symptoms (LUTS) in patients with erectile dysfunction. Materials and Methods A total of 60 patients diagnosed with erectile dysfunction were retrospectively evaluated using the international index of erectile function questionnaire-5 (IIEF-5), intravaginal ejaculatory latency time (IELT) and international prostate symptoms scores (IPSS). After the patients were treated with 5mg tadalafil once a day for three months, their erection, ejaculation and LUTS were assessed again. The fasting levels of blood glucose, total testosterone, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol and total cholesterol were measured. The independent-samples t-test was used to compare the pre- and post-treatment scores of the patients. Results The mean age of the 60 participants was 50.4±7.9 and the mean baseline serum total testosterone, total cholesterol, and fasting blood sugar were 444.6±178.6ng dL-1, 188.7±29.6mg/dL-1,104 (80-360) mg dL-1, respectively. The mean baseline scores were 2.2±1.4 min for IELT, 9.5±3.7 for IIEF-5 and 14.1±4.5 for IPSS. Following the three-month daily 5mg tadalafil treatment, the scores were found to be 3.4±1.9 min, 16.1±4.7, and 10.4±3.8 for IELT, IIEF and IPSS, respectively. When the baseline and post-treatment scores were compared, a statistically significant increase was observed in the IELTs and IIEF-5 values whereas there was a significant decrease in IPSS (p<0.01). Conclusion A daily dose of 5mg tadalafil can be safely used in the treatment of erectile dysfunction and LUTS, that prolongs the ejaculatory latency time.


Assuntos
Humanos , Masculino , Adulto , Idoso , Ereção Peniana/efeitos dos fármacos , Ejaculação/efeitos dos fármacos , Inibidores da Fosfodiesterase 5/administração & dosagem , Sintomas do Trato Urinário Inferior/tratamento farmacológico , Ejaculação Precoce/tratamento farmacológico , Tadalafila/administração & dosagem , Disfunção Erétil/tratamento farmacológico , Testosterona/sangue , Fatores de Tempo , Glicemia/análise , Ereção Peniana/fisiologia , Esquema de Medicação , Colesterol/sangue , Inquéritos e Questionários , Estudos Retrospectivos , Resultado do Tratamento , Estatísticas não Paramétricas , Ejaculação/fisiologia , Sintomas do Trato Urinário Inferior/fisiopatologia , Ejaculação Precoce/fisiopatologia , Disfunção Erétil/fisiopatologia , Pessoa de Meia-Idade
4.
Int. braz. j. urol ; 43(1): 36-46, Jan.-Feb. 2017. tab, graf
Artigo em Inglês | LILACS | ID: biblio-840810

RESUMO

ABSTRACT Objectives The aim of this study was to assess the possible role of HPV in the development of prostate cancer (PCa) and investigate the distribution of the p53 codon 72 polymorphism in PCa in a Turkish population. Materials and methods A total of 96 tissues, which had been obtained using a radical surgery method, formalin-fixed and parafin-embedded, were used in this study. The study group consisted of 60 PCa tissues (open radical prostatectomy) and the control group contained 36 benign prostatic hyperplasia tissues (BPH) (transvesical open prostatectomy). The presence of HPV and the p53 codon 72 polymorphism was investigated in both groups using real-time PCR and pyrosequencing. Results The results of the real-time PCR showed no HPV DNA in any of the 36 BPH tissue samples. HPV-DNA was positive in only 1 of the 60 PCa samples (1.7%). The HPV type of this sample was identified as HPV-57. The distribution of the three genotypes, Arg/Arg, Arg/Pro and Pro/Pro was found to be 45.6, 45.6, and 8.8% in the PCa group and 57.1%, 34.3% and 8.6% in the control group, respectively. Compared with the control group, patients with PCa had a higher frequency of the Arg/Pro genotype and Proline allele (odds ratio (OR)=1.67, 95% confidence interval (CI)=0.68-4.09, p=0.044; OR=1.13, 95% CI=0.76-1.68, p=0.021, respectively). Conclusions The results of the study do not support the hyphothesis that prostate cancer is associated with HPV infection but indicated that Proline allele can be a risk factor in the development of PCa in the Turkish population.


Assuntos
Humanos , Masculino , Idoso , Idoso de 80 Anos ou mais , Papillomaviridae/isolamento & purificação , Polimorfismo Genético , Neoplasias da Próstata/genética , Neoplasias da Próstata/virologia , Proteína Supressora de Tumor p53/genética , Infecções por Papillomavirus/complicações , Prostatectomia , Hiperplasia Prostática/genética , Hiperplasia Prostática/patologia , Hiperplasia Prostática/virologia , Neoplasias da Próstata/cirurgia , Neoplasias da Próstata/patologia , Turquia , Códon/genética , DNA Viral , Prolina/genética , Estudos Retrospectivos , Fatores de Risco , Inclusão em Parafina , Estudos de Associação Genética , Gradação de Tumores , Técnicas de Genotipagem , Reação em Cadeia da Polimerase em Tempo Real , Genótipo , Pessoa de Meia-Idade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA